Internal Reference Number: FOI_6757
Date Request Received: 26/08/2022 00:00:00
Date Request Replied To: 07/09/2022 00:00:00
This response was sent via: By Email
Request Summary: Treatment for Lung Cancer
Request Category: Private Individuals
| Question Number 1: In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following: • Afatinib • Alectinib • Atezolizumab monotherapy • Atezolizumab in combination • Bevacizumab • Brigatinib • Capmatenib • Ceritinib • Crizotinib • Dacomitinib • Dabrafenib with Trametinib • Docetaxel monotherapy • Durvalumab • Erlotinib • Gefitinib • Gemcitabine • Nintedanib with Docetaxel • Nivolumab • Osimertinib • Paclitaxel • Pembrolizumab monotherapy • Pembrolizumab in combination • Pemetrexed with Carboplatin/Cisplatin • Tepotinib • Vinorelbine with Cisplatin/Carboplatin • Any other SACT • Palliative care only | |
| Answer To Question 1: • Afatinib 0 • Alectinib <5 • Atezolizumab monotherapy <5 • Atezolizumab in combination <5 • Bevacizumab 0 • Brigatinib 0 • Capmatenib 0 • Ceritinib 0 • Crizotinib <5 • Dacomitinib 0 • Dabrafenib with Trametinib 0 • Docetaxel monotherapy 0 • Durvalumab 0 • Erlotinib 0 • Gefitinib <5 • Gemcitabine 0 • Nintedanib with Docetaxel 0 • Nivolumab 0 • Osimertinib 10 • Paclitaxel 0 • Pembrolizumab monotherapy 9 • Pembrolizumab in combination 5 • Pemetrexed with Carboplatin/Cisplatin 8 • Tepotinib 0 • Vinorelbine with Cisplatin/Carboplatin 0 • Any other SACT 8 • Palliative care only 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
